



Meet Mike

AGE

72

LOCATION

SOUTH CAROLINA

DIAGNOSED WITH MODERATE-TO-SEVERE
PLAQUE PSORIASIS

1968

STARTED ILUMYA® (TILDRAKIZUMAB) 100 MG/ML

APRIL 2019

Psoriasis Journey

Mike started noticing plaques on his face, legs and knees in his late teens. Soon after, his dermatologist diagnosed him with moderate-to-severe plaque psoriasis

Mike found it difficult to cover his plaques with his clothing and couldn't wear shorts because of visible plaques on his legs.

Over the years, Mike was the most comfortable at work because he could hide his moderate-to-severe plaque psoriasis with corporate clothing.

Mike's moderate-to-severe plaque psoriasis symptoms caused him to skip out on social events because he found it exhausting to explain what moderate-to-severe plaque psoriasis was to others.

Throughout his journey, Mike used a variety of treatments including topicals and light therapy, but these would only temporarily clear his plaques.

“In my late teens, I was supposed to be having the time of my life, but my moderate-to-severe plaque psoriasis symptoms made it hard to participate in activities with friends.”

Finding ILUMYA®

Mike experienced moderate-to-severe plaque psoriasis symptoms for the majority of his life, so he found it was important for him to find a treatment that could provide long-lasting skin clearance.

“If I had to do it all again, I don't think I could've landed with something better.”

Mike was first introduced to ILUMYA® by his dermatologist and he began treatment in April 2019. Now, having been on ILUMYA® for more than three years, Mike says he is almost completely clear of plaques. Results may vary from patient to patient.

Mike travels often, so finding a treatment with a dosing schedule that works within his lifestyle was essential. With just four doses a year after two starter doses, Mike doesn't have to change his plans to maintain his ILUMYA® treatments.

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate-to-severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy. The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%). These are not all of the possible side effects of ILUMYA®. Call your doctor for medical advice.

Road to Lasting Skin Clearance

Mike spends most of his days in the sunshine playing golf. Now that he is experiencing clearance, Mike does not have to worry about his plaques when enjoying the outdoors.

Now that he is retired, Mike was excited to learn that his ILUMYA® treatments would continue to be covered under Medicare Part B.

Mike can now enjoy time with his children and grandchildren without experiencing painful and itchy plaques.

People living with moderate-to-severe psoriasis should talk to their doctor to determine what treatment option may be right for them. For more information about ILUMYA®, and a downloadable doctor discussion guide, visit [ILUMYA.com/talk-with-your-dermatologist](https://www.ilumya.com/talk-with-your-dermatologist).

Learn more about the moderate-to-severe plaque psoriasis journeys of patients like Mike [here](#).

ILUMYA® IS IN IT FOR THE LONG HAUL WITH ME



With ILUMYA®, most people with moderate-to-severe plaque psoriasis can achieve clear or almost clear skin in as little as 12 weeks, and 5 years into treatment, it's still going strong.

Here are some reasons to ask your doctor about ILUMYA®:

- LONG-LASTING RESULTS**
9 out of 10 people who achieved clear or almost clear skin after 1 year were still seeing results 5 years later
- DOSING AROUND YOUR SCHEDULE**
4 doses a year after 2 starter doses

- WORKS FROM THE INSIDE**
ILUMYA® works with the body to balance an overactive immune system, addressing symptoms at the source
- AFFORDABLE TREATMENT**
Eligible patients may pay just \$5 per dose of ILUMYA®*

* \$16,000 maximum program benefit per calendar year. Not valid for patients without commercial insurance coverage or if prescription is paid for by any state or federally funded healthcare program, including but not limited to Medicare, Medicaid, VA, DOD, or TRICARE.

What is ILUMYA?

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ILUMYA?

Do not use ILUMYA if you have had a severe allergic reaction to ILUMYA or any of its ingredients.

Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

- feel faint
- trouble breathing or throat tightness
- swelling of your face, eyelids, lips, mouth, tongue or throat
- chest tightness
- skin rash

ILUMYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA and may treat you for TB before you begin treatment with ILUMYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

- fever, sweats, or chills
- muscle aches
- weight loss
- cough
- warm, red, or painful skin or sores on your body different from your psoriasis
- diarrhea or stomach pain
- shortness of breath
- burning when you urinate or urinating more often than normal
- blood in your phlegm (mucus)

Before receiving ILUMYA, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section “What is the most important information I should know about ILUMYA?”
- have an infection that does not go away or that keeps coming back
- have TB or have been in close contact with someone with TB
- recently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with ILUMYA.
- are pregnant or plan to become pregnant. It is not known if ILUMYA can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if ILUMYA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

It is not known if ILUMYA is safe and effective in children under 18 years of age.

What are the possible side effects of ILUMYA?

ILUMYA may cause serious side effects. See “What is the most important information I should know about ILUMYA?”

The most common side effects of ILUMYA include upper respiratory infections, injection site reactions and diarrhea. These are not all of the possible side effects of ILUMYA. Call your doctor for medical advice about side effects.

You are encouraged to report any negative side effects of ILUMYA to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You are also encouraged to report side effects or ADEs (adverse drug events) to our Drug Safety Department at 1-800-406-7984 or drug.safetyUSA@sunpharma.com (preferred) with as much information as available.

Please read the full [Prescribing Information](#) and [Medication Guide](#) for ILUMYA and discuss any questions with your doctor.